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Results: Figure 1a shows the cube propagation in the coronal 
direction and DVF of the inserts. Mean S-I distance are 
0.16±0.14cm for cube and 0.27±0.12cm for sphere. DVF have 
a mean magnitude scale of 0.00-1.11cm for the 4DCT. The 
mean transition has same dimension, according to the space 
covered by the objects during phases bin. The motion 
direction is obtained by reverse mode, otherwise uncorrected 
track is provided by the DVF module. Graph (Figure1b) shows 
the displacement of 2 ROIs in S-I directions per phases. A 
strong correlation (R2=0.95) with position, time and direction 
of the inserts (cube and sphere) is obtained (Figure 1c). 
 
Conclusions: DIR algorithms and DVF can be used to calculate 
motion object. A strong correlation with ROI mapping and 
spatial-time variable can obtained by 4DCT and hybrid 
deformable grid. Using DVF we can evaluate, adequately, the 
motion direction and distance between points. ROI Center of 
Mass is not reliable with motion. An anthropomorphic 
phantom, with 8 ribs, 2 tumors (Figure1d) is under 
developing, using LEGO® Mindstorms, to evaluate accuracy 
and criticalities in lung district of DIR, DVF and to 
understanding uncertainties on dose mapping during 
radiation, using TLD. 
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Purpose/Objective: IMRT is an established treatment option 
for patients with prostate cancer, as it allows the delivery of 
highly conformal doses to the target whilst lowering doses to 
OARs. In many centres, including ours, the provision of static 
field IMRT has been supplanted by VMAT which offers faster 
treatment times and greater monitor unit efficiency. The 
results of published dosimetric comparisons between IMRT 
and VMAT for prostate cancer have varied, typically with 
small sample sizes. Here we present a retrospective 
dosimetric audit of clinical IMRT and VMAT treatment plans 
for prostate cancer with a large sample size (N = 1344). 
Materials and Methods: Our standard prostate treatment is a 
three dose level integrated simultaneous-boost technique 
based on the CHHiP trial, with a prescription dose of 60Gy in 
20 fractions, delivery of which has moved from five-field 
step-and-shoot IMRT to predominantly single arc VMAT using 
Elekta linear accelerators. Planning is performed using the 
Philips Pinnacle TPS. 
Automatically populated dosimetric summary forms 
(AutoForms) are routinely generated at our centre for the 
purposes of optimisation and reporting. Prostate AutoForms 
were collected and cross-referenced with treatment planning 
system PDF reports to determine which patients were treated 
with IMRT or VMAT. Patients with artificial hip replacements 
were excluded as we do not treat these patients with VMAT. 
All data collection was fully automated. Target, rectum and 
bladder dosimetric statistics were compared using histograms 
and Mann-Whitney U tests, with a significance level of 0.01. 
It should be noted that our standard VMAT inverse 
optimisation class solution is slightly different to the IMRT 
version. However, all plans have been individually optimised 
by suitably trained individuals. 
Results: The volume of rectum receiving 41% of the 
prescription dose or greater, V41%, and V88% were 
significantly lower for VMAT than IMRT. However, V68% and 
V95% were significantly higher. Bladder dose statistics (V68%, 
V81% and V100%) were lower for VMAT but the differences 
were not significant. 
The percentage of the prescription dose covering 99% of each 
target volume, D99%, was significantly higher for VMAT than 
for IMRT. Sharp cut-offs at tolerance values were much more 
pronounced in the histograms for IMRT than for VMAT, 
supporting anecdotal evidence that coverage tolerances are 
more easily achieved using VMAT. Heterogeneity, defined as 
the difference between the maximum and minimum 
percentage dose to 1cc of the target volume, was 
significantly lower for VMAT than IMRT. 
Conclusions: We have performed a large dosimetric audit, 
comparing IMRT and VMAT for prostate cancer. Bladder dose 
statistics are not significantly different. Some rectum dose 
statistics are significantly greater for VMAT and others for 
IMRT. However, VMAT shows a clear advantage over IMRT in 
coverage statistics. Most strikingly of all, the dose to the 
target volume was much more homogeneous for VMAT than 
for IMRT. 
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